Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19466463 | 0.86 | PIK3CA (0.40) | MTORPIK3CAPIK3R1 | |
| SCHEMBL17859890 | 0.81 | PIK3CA (0.43) | MTORPIK3CAPIK3R1 | |
| SCHEMBL19466462 | 0.80 | PIK3CA (0.67) | MTORPIK3CAPIK3R1 | |
| SCHEMBL17859895 | 0.77 | MTOR (0.43) | MTORPIK3CAPIK3R1 | |
| SCHEMBL19466479 | 0.77 | MTOR (0.43) | MTORPIK3CAPIK3R1 | |
| SCHEMBL17859910 | 0.77 | PIK3R1 (0.43) | MTORPIK3CAPIK3R1 | |
| SCHEMBL17859907 | 0.75 | PIK3CA (0.41) | MTORPIK3CAPIK3R1 | |
| SCHEMBL21263157 | 0.72 | PIK3R1 (0.46) | MTORPIK3CAPIK3R1 | |
| SCHEMBL2370376 | 0.71 | MTOR (0.55) | MTORPIK3CAPIK3R1 | |
| SCHEMBL2370380 | 0.71 | MTOR (0.55) | MTORPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | PIK3CA, PIK3CD, PIK3CG | MTOR 14/4885PIK3CA 1/4885PIK3R1 10/4885 |
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | PIK3CA, PIK3CD, PIK3CG | MTOR 14/4885PIK3CA 1/4885PIK3R1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.